Please login to the form below

Not currently logged in


This page shows the latest Breo news and features for those working in and with pharma, biotech and healthcare.

EMA approves GSK’s triple COPD therapy

EMA approves GSK’s triple COPD therapy

GSK has been bringing other new COPD therapies to market - including Advair successor Breo/Relvar (fluticasone furoate and vilanterol) and Anoro (umeclidinium bromide and vilanterol) - but with greater competition in the

Latest news

More from news
Approximately 11 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2013 Pharma deals during May 2013

    First in this was the purchase for $1bn of 21 per cent of the respiratory product royalties Theravance receives, including the royalties on the recently US approved Breo for COPD being

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....